Alzheimer's breakthroughs bring hope, but funding politics loom large
New amyloid-targeting drugs have begun slowing early-stage Alzheimer’s, while researchers push blood tests and next-generation therapies, though political cuts threaten progress.
The 2023 approvals of lecanemab (Leqembi) and donanemab (Kisunla) introduced the first drugs that meaningfully slow Alzheimer’s progression for people with mild cognitive impairment, though they do not halt or reverse the disease and carry bleeding risks. Researchers are now testing tau-targeting agents such as Biogen’s diranersen and an Eisai compound, while new blood tests aim to identify at-risk individuals before symptoms appear.
The scientific community sees a shift from a single-mechanism focus to multiple therapeutic avenues, including potential prevention with GLP-1 drugs. However, recent cancellations of $15 million in grants by the Trump administration raise concerns that politicized funding could stall momentum. Experts stress that early detection and broader public backing are essential to sustain the emerging wave of treatments.
Why it matters
Early-stage Alzheimer’s drugs and diagnostics could extend quality of life, but political funding cuts risk slowing vital research.
In this story
